Vol. 7, Issue 10 , October 2017 Page 1
Total Page:16
File Type:pdf, Size:1020Kb
Load more
Recommended publications
-
Supplementary Data
SUPPLEMENTARY DATA No evidence of increase in calcitonin concentrations or development of C-cell malignancy in response to liraglutide for up to 5 years in the LEADER trial Laszlo Hegedüs MD DMSc; Steven I. Sherman MD; R. Michael Tuttle MD; Bernt J. von Scholten MD; Søren Rasmussen PhD; Julie D. Karsbøl MD; Gilbert H. Daniels MD; LEADER Publication Committee on behalf of the LEADER Trial Investigators Supplementary Table S1. Baseline demographic and disease characteristics of the trial patients randomized to either placebo or liraglutide Placebo (n = 4672) Liraglutide (n = 4668) Age, years Mean±SD 64.4±7.2 64.2±7.2 Men, n (%) 2992 (64) 3011 (64.5) HbA1c (%) Mean±SD 8.7±1.5 8.7±1.6 HbA1c (mmol/mol) Mean±SD 71.1±16.3 71.9±17.0 Diabetes duration Mean±SD 12.9±8.1 12.8±8.0 Calcitonin, ng/L, males Mean±SD 5.9±7.1 5.9±6.6 Median (IQR) 3.9 (1.0–7.7) 3.9 (1.0–7.5) Calcitonin, ng/L, females Mean±SD 1.4±1.8 1.5±2.2 Median (IQR) 1.0 (1.0–1.0) 1.0 (1.0–1.0) eGFR, n (%) Normal (eGFR >90 mL/min/cm2) 1655 (35.4) 1620 (34.7) Mild impairment (eGFR 60–89 mL/min/m2) 1975 (42.3) 1932 (41.4) Moderate impairment (eGFR 30–59 mL/min/m2) 935 (20.0) 999 (21.4) Severe impairment (eGFR <30 mL/min/m2) 107 (2.3) 117 (2.5) Patients with established CV disease aged ≥50 years, 3767 (80.6) 3831 (82.1) n (%) Patients with risk factors for CV disease aged ≥60 905 (19.4) 837 (17.9) years, n (%) Smoking, n (%) Current 563 (12.1) 567 (12.1) Previous 2189 (46.9) 2151 (46.1) Never 1920 (41.1) 1950 (41.8) Use of proton inhibitors, n (%) 1008 (21,6) 1008 (21.6) Use of H2 blockers, n (%) 161 (3.5) 153 (3.3) History of thyroid disease, n (%) 822 (17.6) 804 (17.2) CT, calcitonin; CV, cardiovascular; eGFR, estimated glomerular filtration rate; HbA1c, glycated hemoglobin; H2, histamine 2; IQR, interquartile range; n, number of patients; SD, standard deviation. -
Supplementary Appendix
Supplementary Appendix This appendix has been provided by the authors to give readers additional information about their work. Supplement to: Mann JFE, Ørsted DD, Brown-Frandsen K, et al. Liraglutide and renal outcomes in type 2 diabetes. N Engl J Med 2017;377:839-48. DOI: 10.1056/NEJMoa1616011 Supplementary Appendix Liraglutide and Renal Outcomes in Type 2 Diabetes Johannes F.E. Mann, M.D.,1,2 David D. Ørsted, M.D., Ph.D.,3 Kirstine Brown-Frandsen, M.D.,3 Steven P. Marso, M.D.,4 Neil R. Poulter, F.Med.Sci.,5 Søren Rasmussen, Ph.D,3 Karen Tornøe, M.D., Ph.D.,3 Bernard Zinman, M.D.,6 John B. Buse M.D., Ph.D.,7 on behalf of the LEADER Steering Committee and Investigators 1Friedrich Alexander University of Erlangen, Erlangen, Germany; 2KfH Kidney Center, Munich, Germany; 3Novo Nordisk, Bagsvaerd, Denmark; 4University of Texas Southwestern Medical Center, Dallas, TX, USA; 5Imperial College London, London, UK; 6Lunenfeld– Tanenbaum Research Institute, Mt. Sinai Hospital, University of Toronto, Toronto, Canada; 7University of North Carolina School of Medicine, Chapel Hill, NC, USA Supplementary Methods Page 2 Supplementary Figures and Tables Page 5 Figure S1a. Urinary albumin-to-creatinine: ratio to baseline at 3-year visit in subgroups stratified according to albuminuria at baseline Page 5 Figure S1b. Urinary albumin-to-creatinine during trial in subgroups stratified according to albuminuria at baseline Page 6 Figure S2. Estimated GFR: ratio to baseline at 3-year visit in subgroups stratified according to eGFR at baseline Page 7 Table S1. Microvascular, renal and eye events Page 8 Table S2. -
Scientific Research of the Sco Countries: Synergy and Integration
SCIENTIFIC RESEARCH OF THE SCO COUNTRIES: SYNERGY AND INTEGRATION 上合组织国家的科学研究:协同和一体化 Proceedings of the Date: International Conference June 24 Beijing, China 2020 上合组织国家的科学研究:协同和一体化 国际会议 参与者的英文报告 International Conference “Scientific research of the SCO countries: synergy and integration” Part 1 - Participants’ reports in English 2020年6月24日。中国北京 June 24, 2020. Beijing, PRC Proceedings of the International Conference “Scientific research of the SCO countries: synergy and integration”. Part 1 - Reports in English (June 24, 2020. Beijing, PRC) ISBN 978-5-905695-60-5 这些会议文集结合了会议的材料 - 研究论文和科学工作 者的论文报告。 它考察了职业化人格的技术和社会学问题。 一些文章涉及人格职业化研究问题的理论和方法论方法和原 则。 作者对所引用的出版物,事实,数字,引用,统计数据,专 有名称和其他信息的准确性负责 These Conference Proceedings combine materials of the conference – research papers and thesis reports of scientific workers. They examines tecnical and sociological issues of research issues. Some articles deal with theoretical and methodological approaches and principles of research questions of personality professionalization. Authors are responsible for the accuracy of cited publications, facts, figures, quotations, statistics, proper names and other information. ISBN 978-5-905695-60-5 ©Scientific publishing house Infinity, 2020 ©Group of authors, 2020 CONTENTS ECONOMICS 在经济停滞的情况下确保合作创业的经济安全 Ensuring economic security for cooperative entrepreneurship under conditions of economic stagnation Isachkova Lidiya Nikolaevna, Asanova Natalia Alexandrovna, Hut Saniyat Yunusovna........................................................................................10 -
Saratov Fall Meeting
SSaarraattoovv FFaallll MMeeeettiinngg -- SSFFMM’’1133 SCIENTIFIC PROGRAM 1st International Symposium on Optics and Biophotonics September 25 – 28, 2013 Saratov, Russia CONFERENCES: Optical Technologies in Biophysics & Medicine XV Laser Physics and Photonics XV Spectroscopy and Molecular Modeling XIV Nanobiophotonics IX Microscopic and Low-Coherence Methods in Biomedical and Non-Biomedical Applications VI Internet Biophotonics VI Nonlinear Dynamics and Computational Biophysics IV Low-Dimensional Structures III 17th International School for Junior Scientists and Students on Optics, Laser Physics & Biophotonics September 24 – 27, 2013 Saratov, Russia WORKSHOPS: Modern Optics XII English as a Communicative Tool in the Scientific Community XII Management of High Technologies Commercialization and Regional Innovation Systems X History, Methodology and Philosophy of the Optical Education VI Special events during the Meeting: U.M.N.I.K.: Special session on student reports on Optics, Laser Physics and Biophotonics, awarded by the Russian Foundation on Innovations Publishing Your Manuscript – Useful Tips SHORT COURSES OSA / SPIE Table of contents Organizers…………………………………………………………………………….……....... 2 Chairs and Program Committees………………………………………………….……….… 4 Schedule……………………………………………………………………………….……….. 6 Plenary lectures………………………………………………..…………………..….……….. 11 Optical Technologies in Biophysics & Medicine XV……………………………….………. 12 Laser Physics and Photonics XV ……………………………………………….…………... 18 Spectroscopy and Molecular Modeling XIV………………..………………………………. 21